ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2021年07月30日 10時00分
Source:
Eisai
エーザイ、社会的責任投資指数「FTSE4Good Index Series」の対象銘柄に20年連続で選定
東京, 2021年07月30日 - (JCN Newswire) - エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫)は、このたび、社会的責任投資の代表的な指数である「FTSE4Good Index Series」の構成銘柄に、2002年以来20年連続で選定されましたのでお知らせします。
「FTSE4Good Index Series」は、環境・社会・ガバナンス(ESG)のグローバル・スタンダードを満たす企業への投資を促進するようデザインされた株式指数シリーズです。当社は評価項目のうち、「コーポレートガバナンス」、「人権と地域社会」、「労働基準」、および「腐敗防止」などの項目において特に高い評価を受けました。2021年6月末現在、世界で1,045社、日本企業ではそのうち204社が「FTSE4Good Developed Index」に選定されています。
当社は、「FTSE4Good Index Series」以外にも年金積立金管理運用独立行政法人(GPIF)によって採用されている日本株の4つのESG投資指数である「MSCI 日本株女性活躍指数(WIN)」、「FTSE Blossom Japan Index」、「MSCIジャパンESGセレクト・リーダーズ指数」および「S&P/JPXカーボンエフィシエント指数」にも選定されています。
当社は、患者様とそのご家族の喜怒哀楽を第一義に考え、そのベネフィット向上に貢献し、世界のヘルスケアの多様なニーズを充足することを企業理念と定めています。当社は、この理念の実現のために、ESGへの取り組みを強化し、非財務価値を高めることにより、持続的企業価値向上に努めてまいります。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2021/news202163.html
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
New-look TGR-WRT launches landmark campaign on legendary rally
Jan 16, 2026 21:34 JST
Mitsubishi Corporation Announces Acquisition of Haynesville Shale Gas Business in Louisiana and Texas
Jan 16, 2026 21:12 JST
MHI Thermal Systems Expands Lineup of Building-Use Multi-Split Air-Conditioners for Overseas Markets
Jan 16, 2026 15:47 JST
NEC Launches "NEC Composable Disaggregated Infrastructure Solution" for Distributed Computing Resources
Jan 15, 2026 17:00 JST
Mitsubishi Power Lands Significant Gas Turbine Order for Qatar's Facility E IWPP Project
Jan 14, 2026 18:58 JST
Mitsubishi Motors Launches Updated Outlander PHEV in Canada
Jan 14, 2026 17:38 JST
Hitachi High-Tech launches FOUNDRY-MASTER Smart 2, enhancing performance and value of stationary optical emission spectrometers
Jan 14, 2026 14:10 JST
Fujitsu launches demonstration experiment into green steel value flow utilizing blockchain technology to accelerate decarbonization in the steel Industry
Jan 14, 2026 10:52 JST
Toyota Systems, Fujitsu utilize quantum-inspired technology and AI to streamline on-board computer design and contribute to sustainable development
Jan 14, 2026 10:36 JST
Mitsubishi Motors Starts Production of Rogue Plug-in Hybrid and Navara OEM Models for Nissan
Jan 13, 2026 16:02 JST
Additional Investment in Commercial Space Station Business and Acquisition of Experimental Module Usage Rights
Jan 13, 2026 14:34 JST
Honda to Adopt New "H mark" as Symbol of Honda Automobile Business
Jan 13, 2026 11:26 JST
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
Jan 13, 2026 09:50 JST
Mazda Unveils MAZDA CX-6e New Battery EV in World Premiere
Jan 12, 2026 13:10 JST
TOYOTA GAZOO Racing Announces GR Yaris MORIZO RR
Jan 09, 2026 16:03 JST
Honda Announces New Lines of Models that Represent "Honda Sports DNA" at Tokyo Auto Salon 2026
Jan 09, 2026 14:24 JST
Honda Launches Fixed-Battery Electric Two-Wheeled Personal Commuter "Honda UC3" in Thailand and Vietnam
Jan 09, 2026 13:27 JST
Sponsorship Agreement Reached with LCR Honda; Full-Season MotoGP Entry as Pro Honda LCR
Jan 09, 2026 13:05 JST
Mazda Develops New Body Color, "Navy Blue Mica"
Jan 09, 2026 10:23 JST
Fujitsu develops digital learning platform for JAL to support self-directed learning and training management
Jan 09, 2026 10:07 JST
More Latest Release >>
Related Release
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
1/13/2026 9:50:00 AM JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
1/6/2026 10:43:00 AM JST
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
12/11/2025 7:41:00 PM JST
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
12/9/2025 6:51:00 PM JST
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025
12/4/2025 6:36:00 PM JST
New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
12/3/2025 6:19:00 PM JST
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
12/3/2025 12:01:00 AM JST
Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
11/28/2025 11:00:00 PM JST
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
11/26/2025 7:42:00 PM JST
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom
11/17/2025 10:08:00 PM JST
More Press release >>